Evidence map›Paper›PMID 40772513›Full record

ReviewCurrent opinion in HIV and AIDS2025

Single cell technologies and the biology of HIV-infected CD4 T-cell reservoirs.

Pavitra Ramdas, Ramón A Lujan, Prakriti Mudvari, Liliana Pérez, Eli A Boritz

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pavitra RamdasVirus Persistence and Dynamics Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Ramón A Lujan
Prakriti Mudvari
Liliana Pérez
Eli A Boritz

Funding

HIV persistence in vivoZIAAI005131 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2017 to 2025
$14.5M
Intramural NIH HHS ZIA AI005131
6 · The paper itself

Abstract

purpose of reviewAlthough populations of rare HIV-infected CD4 T cells that persist under antiretroviral therapy (ART) are believed to be a major barrier to HIV cure, technical obstacles have made it impossible to determine whether these cells possess distinctive attributes that enable their persistence. Here we review the development of technologies that have begun to allow HIV-infected cells in their natural state to be described comprehensively. RECENT

findingsAs widely used platforms that analyze single-cells within water-in-oil droplets have yielded information about HIV-infected CD4 T cells ex vivo, adaptations of these platforms and custom workflows that address additional technical obstacles specific to some HIV-infected cells have also been developed. These advancements, combined with analyses of defined participant cohorts, tissue-derived cells, and unique clinical scenarios, have provided mounting evidence that HIV-infected cells under ART have distinctive host transcriptomic and epigenetic profiles that may help explain their persistence in vivo. SUMMARY: Single-cell analytical technologies that can comprehensively describe the biology of HIV-infected cells under ART promise new discoveries that may accelerate development of safe and scalable HIV cure strategies.

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsSingle-Cell AnalysisHumansHIV reservoirmechanisms of HIV persistencemicrofluidicssingle-cell analysis

Identifiers

PMID40772513
PMCPMC12333547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.